Walnut Creek, CA, United States of America

Christopher Joseph Sinz

USPTO Granted Patents = 3 

Average Co-Inventor Count = 8.6

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2023-2025

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations by Christopher Joseph Sinz

Introduction

Christopher Joseph Sinz, based in Walnut Creek, California, is a notable inventor with three patents to his name. His contributions to the field of biochemistry have led to significant advancements in medical science, particularly concerning APOL1 inhibitors.

Latest Patents

Sinz's most recent patents focus on APOL1 inhibitors and their methods of use. He has developed compounds that showcase a specific formula aimed at inhibiting APOL1, which is critical for treating APOL1-mediated diseases and conditions. These patents not only detail the compounds but also outline methods for preparing these compounds, ensuring clarity in their application and utility.

Career Highlights

Currently, Sinz is affiliated with Maze Therapeutics, Inc., a company known for its innovative approach to genetic diseases. His role at Maze Therapeutics allows him to leverage his expertise and contribute to the development of therapies that directly impact patient care.

Collaborations

Sinz works alongside talented colleagues such as David John Morgans, Jr. and Patrick Sang Tae Lee. This collaboration fosters a rich environment for innovation and the sharing of ideas, enabling the team to push the boundaries of what is possible in their field.

Conclusion

Christopher Joseph Sinz has made substantial contributions to medical science through his innovative patents and collaborative efforts at Maze Therapeutics, Inc. His work in developing APOL1 inhibitors represents a significant advancement in potential treatments for related diseases, showcasing the importance of ongoing research and innovation in the health sector.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…